UK markets close in 35 minutes
  • FTSE 100

    6,989.24
    +4.65 (+0.07%)
     
  • FTSE 250

    17,186.22
    -117.89 (-0.68%)
     
  • AIM

    811.02
    -10.33 (-1.26%)
     
  • GBP/EUR

    1.1154
    -0.0022 (-0.19%)
     
  • GBP/USD

    1.0743
    +0.0012 (+0.11%)
     
  • BTC-GBP

    18,097.37
    -836.15 (-4.42%)
     
  • CMC Crypto 200

    443.12
    +14.34 (+3.34%)
     
  • S&P 500

    3,684.26
    +36.97 (+1.01%)
     
  • DOW

    29,429.83
    +294.84 (+1.01%)
     
  • CRUDE OIL

    80.53
    +2.03 (+2.59%)
     
  • GOLD FUTURES

    1,659.20
    +23.00 (+1.41%)
     
  • NIKKEI 225

    26,173.98
    -397.89 (-1.50%)
     
  • HANG SENG

    17,250.88
    -609.43 (-3.41%)
     
  • DAX

    12,123.87
    -15.81 (-0.13%)
     
  • CAC 40

    5,738.23
    -15.59 (-0.27%)
     

Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference

·4-min read
Addex Therapeutics
Addex Therapeutics

Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will present at both the Sachs Associates 22nd Annual Biotech in Europe forum in Basel, Switzerland and the Baader Investment Conference in Munich, Germany taking place September 21 - 22, 2022 and September 23, 2022, respectively.

In his presentations, Mr. Dyer will provide a corporate update and discuss recent developments at Addex. A video of each presentation will be available for viewing on-demand by registered participants.

Mr. Dyer will also participate in a neurodegenerative diseases roundtable discussion with other panelists at the Sachs Associates Conference, scheduled on September 22, 2022.

Mr. Dyer will be available for one-on-one meetings throughout both conferences. For more information or to schedule a one-on-one meeting, please contact IR@addexpharma.com.

About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAMs for CMT1A, chronic cough and several types of pain, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, M4 PAM for schizophrenia and other forms of psychosis, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.

Press Contacts:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
PR@addextherapeutics.com

Mike Sinclair
Partner, Halsin Partners
+44 (0)7968 022075
msinclair@halsin.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including the ability to discover molecules as part of the Indivior collaboration, the progress of clinical trials and preclinical studies, including the timing of data read-outs from the ADX71149 epilepsy study, and our intended strategic direction. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as receipt of ongoing research payments and timing of the collaboration conclusion, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2021, as filed with the SEC on March 10, 2022, the prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.